Novo Nordisk Reveals Interim Data from P-III (FRONTIER3) Trial of Mim8 for Haemophilia A with or without Inhibitors
Shots:
- The P-III (FRONTIER3) trial assessed Mim8 (SC) in 70 pts (1-11yrs.) with hemophilia A ± FVIII inhibitors in 2 parts: P1 involves Q1W prophylaxis therapy until 26wks. after which pts can stay on Q1W or switch to QM for further 26wks.; regulatory filings expected in 2025
- P1 data showed 0.53 mean & 0 median ABR, with 74.3% pts (incl.14 hemophilia A pts with inhibitors) having 0 treated bleeds. After 26wks., 45% switched to Mim8 (QM)
- Pts- & caregiver-reported data from P1 showed that Mim8 might reduce treatment burden with positive trends observed in physical function & QoL scores in 26wks. Data presented at EAHAD 2025; full data to be presented in future meetings & publications (2025-26)
Ref: Globenewswire | Image: Novo Nordisk
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
